UT-Southwestern Medical Center: How an Experimental Drug Reverses Fatty Liver Disease
February 29, 2024
February 29, 2024
DALLAS, Texas, Feb. 29 (TNSres) -- The University of Texas Southwestern Medical Center issued the following news release:
A drug in clinical trials as a treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) works with a one-two punch that shuts down triglyceride production and fatty acid synthesis in liver cells, UT Southwestern Medical Center researchers show in a new study. Their findings, published in Cell Metabolism, shed light not only on the mechanism . . .
A drug in clinical trials as a treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) works with a one-two punch that shuts down triglyceride production and fatty acid synthesis in liver cells, UT Southwestern Medical Center researchers show in a new study. Their findings, published in Cell Metabolism, shed light not only on the mechanism . . .